Promising cancer combo trial halted early – what it means for patients
Disease control
Terminated
This study tested a combination of two drugs, ulixertinib and hydroxychloroquine, in 47 adults with advanced gastrointestinal cancers (like stomach, pancreatic, or colorectal) that have specific gene changes in the MAPK pathway. The goal was to see if the combo could shrink tumor…
Phase: PHASE2 • Sponsor: BioMed Valley Discoveries, Inc • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC